世界の遺伝子治療細胞培養培地市場2020年-2027年:培地種類別(血清含有培地、無血清培地、幹細胞培地、特殊培地、合成培地、溶原培地、カスタム培地、その他)、ウイルスベクター別、エンドユーザー別

◆英語タイトル:Gene Therapy Cell Culture Media Market by Media Type (Serum Containing Media, Serum Free Media, Stem Cell Media, Specialty Media, Chemically Defined Media, Lysogeny Broth, Custom Media, and Others), Viral Vectors Type (Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, and Others), and End User (Biotechnology & Pharmaceutical Industry, Academic Institute, Research Laboratory, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
◆商品コード:AMR21MC005
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2021年1月12日
◆ページ数:262
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD6,168 ⇒換算¥703,152見積依頼/購入/質問フォーム
5 UserUSD6,929 ⇒換算¥789,906見積依頼/購入/質問フォーム
Enterprise UserUSD9,663 ⇒換算¥1,101,582見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Allied Market Research社の本調査レポートでは、世界の遺伝子治療細胞培養培地市場について調査し、イントロダクション、エグゼクティブサマリー、市場概要、培地種類別(血清含有培地、無血清培地、幹細胞培地、特殊培地、合成培地、溶原培地、カスタム培地、その他)分析、ウイルスベクター別(レトロウイルス、レンチウイルス、アデノウイルス、アデノ随伴ウイルス、単純ヘルペスウイルス、その他)分析、エンドユーザー別(製薬・バイオテクノロジー産業、研究所、学術機関、その他)分析、地域別分析などを掲載しています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の遺伝子治療細胞培養培地市場規模:培地種類別(血清含有培地、無血清培地、幹細胞培地、特殊培地、合成培地、溶原培地、カスタム培地、その他)
・世界の遺伝子治療細胞培養培地市場規模:ウイルスベクター別(レトロウイルス、レンチウイルス、アデノウイルス、アデノ随伴ウイルス、単純ヘルペスウイルス、その他)
・世界の遺伝子治療細胞培養培地市場規模:エンドユーザー別(製薬・バイオテクノロジー産業、研究所、学術機関、その他)
・世界の遺伝子治療細胞培養培地市場規模:地域別
【レポートの概要】

The global gene therapy cell culture media market accounted for $122.60 million in 2019, and is expected to reach $278.96 million by 2027, registering a CAGR of 10.6% from 2020 to 2027.
Gene therapy cell culture media consists of important nutrients that provide ample energy to regulate healthy cell cycle. Moreover, it contains bovine serum, animal-derived nutrients, and growth factors like EGF, FGF, IGF, and PDGF. A surge in R&D activities worldwide are prime factor for the growth of the gene therapy cell culture media. Various pharmaceutical and biotechnology companies are heavily investing in R&D of gene therapy. Culture media are nutrient growth substances provided in laboratory and research settings for growth, proliferation, maintenance, and storage of microorganisms and other cell types such as stem cells, mammalian, and other cell lines. Different culture media are available in the market for various cell cultures to survive and grow in their incubation environment.
Viral vectors include all viruses that can be used as vectors for the transfer of genes into a host cell. These vectors are further categorized into retroviruses, lentiviruses, adenoviruses, adeno-associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Many gene therapy clinical trials have been conducted that make use of retroviruses or adenoviruses to deliver the desired gene. These viruses vary in regards with the mechanism of transferring the genes to those cells which they can recognize and then they infect, which leads to change in the cell’s DNA permanently or temporarily.

The market growth is driven due to factors such as rise in R&D investments, and growth in awareness regarding gene therapy. However, dearth of skilled professionals, high costs associated with gene therapies, and ethical & scientific concerns associated with culture media hamper the market growth. Moreover, untapped potential of the emerging economies is expected to offer opportunities for gene therapy cell culture market growth during the forecast period.
The segment is divided into media type, viral vectors type, end user, and region. By media type is further divided into serum containing media, serum free media, stem cell media, specialty media, chemically defined media, lysogeny broth, custom media, and others. In addition, the viral vectors are divided into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Further, by end user, the market is classified into biotechnology & pharmaceutical industry, academic institute, research laboratory, and others. By region, the gene therapy cell culture media market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The gene therapy cell culture media market provides extensive competitive analysis and profiles of key market players, such as Fujifilm Holdings Corporation, HiMedia Laboratories Pvt., Ltd, Lonza Group Ltd, Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Takara Holdings Inc., Novartis International AG, and Bio-Techne Corporation.

KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis of the current market trends from 2019 to 2027 to identify the prevailing opportunities.
• The gene therapy cell culture media market size and estimations are based on comprehensive analysis of the key developments in the industry.
• In-depth analysis based on region assists to understand the regional market and the strategic business planning.
• The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS
By Media Type
• Serum-containing Media
• Serum-free Media
• Stem Cell Media
• Specialty Media
• Chemically Defined Media
• Lysogeny Broth
• Custom Media
• Others

By Viral Vectors Type
• Retroviruses
• Lentiviruses
• Adenoviruses
• Adeno-associated Virus
• Herpes Simplex Virus
• Poxvirus
• Vaccinia Virus
• Others

By End-User
• Biotechnology & Pharmaceutical Industry
• Academic Institute
• Research Laboratory
• Others

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Fujifilm Holdings Corporation
• HiMedia Laboratories Pvt., Ltd
• Lonza Group Ltd
• Sartorius AG (S
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Danaher Corporation
• Takara Holdings Inc.
• Novartis International AG
• Bio-Techne Corporation

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Top player positioning
3.4.Porter’s five forces analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in R&D investments
3.5.1.2.Growth in awareness regarding gene therapy
3.5.1.3.Increase in advancements associated gene therapy
3.5.1.4.Increase in prevalence of cancer

3.5.2.Restraints

3.5.2.1.Dearth of skilled professionals
3.5.2.2.High cost associated with gene therapies
3.5.2.3.Ethical & scientific concerns associated with culture media

3.5.3.Opportunity

3.5.3.1.Untapped potential of the emerging economies

3.6.Impact Analysis of COVID-19 on Gene Therapy Cell Culture Media Market

CHAPTER 4:GENE THERAPY CELL CULTURE MEDIA MARKET, BY
MEDIA TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Serum-containing media

4.2.1.Market size and forecast, by region
4.2.2.Market analysis by country

4.3.Serum-free media

4.3.1.Market size and forecast, by region
4.3.2.Market analysis by country

4.4.Stem cell media

4.4.1.Market size and forecast, by region
4.4.2.Market analysis by country

4.5.Specialty media

4.5.1.Market size and forecast, by region
4.5.2.Market analysis by country

4.6.Chemically defined media

4.6.1.Market size and forecast, by region
4.6.2.Market analysis by country

4.7.Lysogeny broth

4.7.1.Market size and forecast, by region
4.7.2.Market analysis by country

4.8.Custom media

4.8.1.Market size and forecast, by region
4.8.2.Market analysis by country

4.9.Other media

4.9.1.Market size and forecast, by region
4.9.2.Market analysis by country

CHAPTER 5:GENE THERAPY CELL CULTURE MEDIA MARKET, BY
VIRAL VECTORS TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Retroviruses

5.2.1.Market size and forecast, by region
5.2.2.Market analysis by country

5.3.Lentiviruses

5.3.1.Market size and forecast, by region
5.3.2.Market analysis by country

5.4.Adenoviruses

5.4.1.Market size and forecast, by region
5.4.2.Market analysis by country

5.5.Adeno associated virus

5.5.1.Market size and forecast, by region
5.5.2.Market analysis by country

5.6.Herpes simplex virus

5.6.1.Market size and forecast, by region
5.6.2.Market analysis by country

5.7.Poxvirus

5.7.1.Market size and forecast, by region
5.7.2.Market analysis by country

5.8.Vaccinia virus

5.8.1.Market size and forecast, by region
5.8.2.Market analysis by country

5.9.Others

5.9.1.Market size and forecast, by region
5.9.2.Market analysis by country

CHAPTER 6:GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Pharmaceutical & biotechnology Industries

6.2.1.Market size and forecast, by region
6.2.2.Market analysis by country

6.3.Research Laboratories

6.3.1.Market size and forecast, by region
6.3.2.Market analysis by country

6.4.Academic Institutions

6.4.1.Market size and forecast, by region
6.4.2.Market analysis by country

6.5.Others

6.5.1.Market size and forecast, by region
6.5.2.Market analysis by country

CHAPTER 7:GENE THERAPY CELL CULTURE MEDIA MARKET, BY REGION

7.1.OVERVIEW

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities
7.2.2.North America cell culture market, by country

7.2.2.1.U.S. gene therapy cell culture media market, by media type
7.2.2.2.U.S. gene therapy cell culture media market, by viral vectors type
7.2.2.3.U.S. gene therapy cell culture media market, by end user
7.2.2.4.Canada gene therapy cell culture media market, by media type
7.2.2.5.Canada gene therapy cell culture media market, by viral
vectors type
7.2.2.6.Canada gene therapy cell culture media market, by end user
7.2.2.7.Mexico gene therapy cell culture media market, by media type
7.2.2.8.Mexico gene therapy cell culture media market, by viral vectors type
7.2.2.9.Mexico gene therapy cell culture media market, by end user

7.2.3.North America gene therapy cell culture media market, by media type
7.2.4.North America gene therapy cell culture media market, by viral
vectors type
7.2.5.North America gene therapy cell culture media market, by end user

7.3.Europe

7.3.1.Key market trends and opportunities
7.3.2.Europe gene therapy cell culture media market, by country

7.3.2.1.Germany gene therapy cell culture media market, by media type
7.3.2.2.Germany gene therapy cell culture media market, by viral
vectors type

7.3.2.3.Germany gene therapy cell culture media market, by end user
7.3.2.4.France gene therapy cell culture media market, by media type
7.3.2.5.France gene therapy cell culture media market, by viral vectors type
7.3.2.6.France gene therapy cell culture media market, by end user
7.3.2.7.UK gene therapy cell culture media market, by media type
7.3.2.8.UK gene therapy cell culture media market, by viral vectors type
7.3.2.9.Uk gene therapy cell culture media market, by end user
7.3.2.10.Italy gene therapy cell culture media market, by media type
7.3.2.11.Italy gene therapy cell culture media market, by viral vectors type
7.3.2.12.Italy gene therapy cell culture media market, by end user
7.3.2.13.Spain gene therapy cell culture media market, by media type
7.3.2.14.Spain gene therapy cell culture media market, by viral vectors type
7.3.2.15.Spain gene therapy cell culture media market, by end user
7.3.2.16.Rest of Europe gene therapy cell culture media market,
by media type
7.3.2.17.Rest of Europe gene therapy cell culture media market,
by viral vectors type
7.3.2.18.Rest of Europe gene therapy cell culture media market, by end user

7.3.3.Europe gene therapy cell culture media market, by media type
7.3.4.Europe gene therapy cell culture media market, by viral vectors type
7.3.5.Europe gene therapy cell culture media market, by end user

7.4.Asia-Pacifi

7.4.1.Key market trends and opportunities
7.4.2.Asia-Pacific gene therapy cell culture media market, by country

7.4.2.1.China gene therapy cell culture media market, by media type
7.4.2.2.China gene therapy cell culture media market, by viral vectors type
7.4.2.3.China gene therapy cell culture media market, by end user
7.4.2.4.Japan gene therapy cell culture media market, by media type
7.4.2.5.Japan gene therapy cell culture media market, by viral vectors type
7.4.2.6.Japan gene therapy cell culture media market, by end user
7.4.2.7.Australia gene therapy cell culture media market, by media type
7.4.2.8.Australia gene therapy cell culture media market, by viral
vectors type
7.4.2.9.Australia gene therapy cell culture media market, by end user
7.4.2.10.India gene therapy cell culture media market, by media type
7.4.2.11.India gene therapy cell culture media market, by viral vectors type
7.4.2.12.India gene therapy cell culture media market, by end user
7.4.2.13.South Korea gene therapy cell culture media market, by media type
7.4.2.14.South Korea gene therapy cell culture media market, by viral
vectors type
7.4.2.15.South Korea gene therapy cell culture media market, by end user
7.4.2.16.Rest of Asia-Pacific gene therapy cell culture media market,
by media type
7.4.2.17.Rest of Asia-Pacific gene therapy cell culture media market,
by viral vectors type
7.4.2.18.Rest of Asia- Pacific gene therapy cell culture media market,
by end user

7.4.3.Asia- Pacific gene therapy cell culture media market, by media type
7.4.4.Asia- Pacific gene therapy cell culture media market, by
viral vectors type
7.4.5.Asia- Pacific gene therapy cell culture media market, by end user

7.5.LAMEA

7.5.1.Key market trends and opportunities
7.5.2.LAMEA gene therapy cell culture media market, by country

7.5.2.1.Brazil gene therapy cell culture media market, by media type
7.5.2.2.Brazil gene therapy cell culture media market, by viral vectors type

7.5.3.Brazil gene therapy cell culture media market, by end user

7.5.3.1.Saudi Arabia gene therapy cell culture media market,
by media type
7.5.3.2.Saudi Arabia gene therapy cell culture media market, by
viral vectors type

7.5.4.Saudi Arabia gene therapy cell culture media market, by end user

7.5.4.1.South Africa gene therapy cell culture media market, by media type
7.5.4.2.South Africa gene therapy cell culture media market, by viral
vectors type

7.5.5.South Africa gene therapy cell culture media market, by end user

7.5.5.1.Rest of LAMEA gene therapy cell culture media market,
by media type
7.5.5.2.Rest of LAMEA gene therapy cell culture media market, by
viral vectors type

7.5.6.REST OF LAMEA gene therapy cell culture media market, by end user
7.5.7.LAMEA gene therapy cell culture media market, by media type
7.5.8.LAMEA gene therapy cell culture media market, by viral vectors type
7.5.9.LAMEA gene therapy cell culture media market, by end user

CHAPTER 8:COMPANY PROFILES

8.1.BIO-TECHNE CORPORATION

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Operating product portfolio
8.1.5.Business performance

8.2.DANAHER CORPORATION (CYTIVA)

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance

8.3.FUJIFILM HOLDINGS CORPORATION (FUJIFILM IRVINE SCIENTIFIC)

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments

8.4.HIMEDIA LABORATORIES

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio

8.5.LONZA GROUP LTD

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Operating product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.MERCK KGAA

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.NOVARTIS INTERNATIONAL AG

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.SARTORIUS AG

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.THERMO FISHER SCIENTIFIC, INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.TAKARA HOLDINGS INC. (TAKARA BIO INC.)

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.GENE THERPAY CELL CULTURE MEDIA MARKET BY MEDIA TYPE 2019-2027, ($MILLION)
TABLE 02.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SERUM CONTAINING MEDIA, BY REGION
2019–2027($MILLION)
TABLE 03.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SERUM FREE MEDIA, BY REGION
2019–2027($MILLION)
TABLE 04.GENE THERAPY CELL CULTURE MEDIA MARKET FOR STEM CELL MEDIA, BY REGION
2019–2027($MILLION)
TABLE 05.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SPECIALTY MEDIA, BY REGION
2019–2027($MILLION)
TABLE 06.GENE THERAPY CELL CULTURE MEDIA MARKET FOR CHEMICALLY DEFINED MEDIA,
BY REGION 2019–2027($MILLION)
TABLE 07.GENE THERAPY CELL CULTURE MEDIA MARKET FOR LYSOGENY BROTH, BY REGION
2019–2027($MILLION)
TABLE 08.GENE THERAPY CELL CULTURE MEDIA MARKET FOR CUSTOM MEDIA, BY REGION
2019–2027($MILLION)
TABLE 09.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHER MEDIA, BY REGION
2019–2027($MILLION)
TABLE 10.GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
TABLE 11.GENE THERAPY CELL CULTURE MEDIA MARKET FOR RETROVIRUSES, BY REGION
2019–2027($MILLION)
TABLE 12.GENE THERAPY CELL CULTURE MEDIA MARKET FOR LENTIVIRUSES, BY REGION
2019–2027($MILLION)
TABLE 13.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ADENOVIRUSES, BY REGION
2019–2027($MILLION)
TABLE 14.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ADENO ASSOCIATED VIRUS, BY REGION
2019–2027($MILLION)
TABLE 15.GENE THERAPY CELL CULTURE MEDIA MARKET FOR HERPES SIMPLEX VIRUS, BY REGION
2019–2027($MILLION)
TABLE 16.GENE THERAPY CELL CULTURE MEDIA MARKET FOR POXVIRUS, BY REGION 2019–2027($MILLION)
TABLE 17.GENE THERAPY CELL CULTURE MEDIA MARKET FOR VACCINIA VIRUS, BY REGION
2019–2027($MILLION)
TABLE 18.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHERS, BY REGION 2019–2027($MILLION)
TABLE 19.GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 20.GENE THERAPY CELL CULTURE MEDIA MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY
INDUSTRIES, BY REGION 2019–2027($MILLION)
TABLE 21.GENE THERAPY CELL CULTURE MEDIA MARKET FOR RESEARCH LABORATORIES, BY REGION
2019–2027 ($MILLION)
TABLE 22.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ACADEMIC INSTITUTIONS, BY REGION
2019–2027 ($MILLION)
TABLE 23.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHERS, BY REGION 2019–2027 ($MILLION)
TABLE 24.GENE THERAPY CELL CULTURE MEDIA MARKET REVENUE, BY REGION, 2019–2027($MILLION)
TABLE 25.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY,
2019–2027($MILLION)
TABLE 26.U.S. GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 27.U.S. GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
TABLE 28.U.S. GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 29.CANADA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 30.CANADA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 31.CANADA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 32.MEXICO GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 33.MEXICO GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 34.MEXICO GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 35.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 36.NORTH AMERICA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 37.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
2019–2027($MILLION)
TABLE 38.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 39.GERMANY GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 40.GERMANY GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 41.GERMANY GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 42.FRANCE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 43.FRANCE GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 44.FRANCE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 45.UK GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 46.UK GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
TABLE 47.UK GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 48.ITALY GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 49.ITALY GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
TABLE 50.ITALY GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 51.SPAIN GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 52.SPAIN GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 53.SPAIN GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 54.REST OF EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 55.REST OF EUROPE GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 56.REST OF EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
2019–2027($MILLION)
TABLE 57.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 58.EUROPE GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 59.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 60.ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 61.CHINA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 62.CHINA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 63.CHINA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 64.JAPAN GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 65.JAPAN GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 66.JAPAN GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 67.AUSTRALIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 68.AUSTRALIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 69.AUSTRALIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 70.INDIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 71.INDIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
TABLE 72.INDIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 73.SOUTH KOREA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 74.SOUTH KOREA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 75.SOUTH KOREA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 76.REST OF ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 77.REST OF ASIA-PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 78.REST OF ASIA PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
2019–2027($MILLION)
TABLE 79.ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 80.ASIA PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 81.ASIA- PACIFC GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 82.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 83.BRAZIL GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 84.BRAZIL GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 85.BRAZIL GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 86.SAUDI ARABIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 87.SAUDI ARABIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 88.SAUDI ARABIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 89.SOUTH AFRICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 90.SOUTH AFRICA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 91.SOUTH AFRICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
2019–2027($MILLION)
TABLE 92.REST OF LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 93.REST OF LAMEA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 94.REST OF LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
2019–2027($MILLION)20
TABLE 95.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 96.ASIA PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 97.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 98.BIO-TECHNE: COMPANY SNAPSHOT
TABLE 99.OPERATING BUSINESS SEGMENT
TABLE 100.BIO-TECHNE: PRODUCT PORTFOLIO
TABLE 101.DANAHER: COMPANY SNAPSHOT
TABLE 102.DANAHER: OPERATING SEGMENT
TABLE 103.GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 104.FUJIFILM: COMPANY SNAPSHOT
TABLE 105.FUJIFILM: OPERATING SEGMENTS
TABLE 106.FUJIFILM: PRODUCT PORTFOLIO
TABLE 107.HIMEDIA: COMPANY SNAPSHOT
TABLE 108.HIMEDIA:OPERATING PRODUCT SEGMENT
TABLE 109.HIMEDIA: PRODUCT PORTFOLIO
TABLE 110.LONZA: COMPANY SNAPSHOT
TABLE 111.PRODUCT PORTFOLIO
TABLE 112.LONZA: PRODUCT PORTFOLIO
TABLE 113.SARTORIUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.MERCK: COMPANY SNAPSHOT
TABLE 115.MERCK: OPERATING SEGMENTS
TABLE 116.MERCK: PRODUCT PORTFOLIO
TABLE 117.SARTORIUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118.NOVARTIS: COMPANY SNAPSHOT
TABLE 119.NOVARTIS: OPERATING SEGMENTS
TABLE 120.NOVARTIS: PRODUCT PORTFOLIO
TABLE 121.SARTORIUS: COMPANY SNAPSHOT
TABLE 122.SARTORIUS: OPERATING BUSINESS SEGMENTS
TABLE 123.SARTORIUS: PRODUCT PORTFOLIO
TABLE 124.THERMO FISHER: COMPANY SNAPSHOT
TABLE 125.THERMO FISHER.: OPERATING SEGMENTS
TABLE 126.THERMO FISHER.: PRODUCT PORTFOLIO
TABLE 127.THERMO FISHER SCIENTIFIC : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 128.TAKARA GROUP: COMPANY SNAPSHOT
TABLE 129.TAKARA GROUP: OPERATING SEGMENTS
TABLE 130.TAKARA GROUP: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GENE THERAPY CELL CULTURE MEDIA MARKETSEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020*
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020*
FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
FIGURE 07.LOW BARGAINING POWER OF SUPPLIERS
FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
FIGURE 09.LOW THREAT OF SUBSTITUTION
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 12.GENE THERAPY PIPELINE VOLUME, PRECLINICAL THROUGH PRE-REGISTRATION PHASE, 1995–2018
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
SERUM CONTAINING MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
SERUM FREE MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
STEM CELL MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
SPECIALTY MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
CHEMICALLY DEFINED MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
LYSOGENY BROTH, BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
CUSTOM MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
OTHER MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
RETROVIRUSES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
LENTIVIRUSES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
ADENOVIRUSES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
ADENO ASSOCIATED VIRUS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
HERPES SIMPLEX VIRUS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
POXVIRUS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
VACCINIA VIRUS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
RESEARCH LABORATORIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 31.COMPARATIVE SHARE ANALYSIS OF CELL CULTURE MARKET FOR ACADEMIC INSTITUTIONS,
BY COUNTRY, 2019 & 2027 (%)
FIGURE 32.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 33.BIO-TECHNE: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.BIO-TECHNE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.BIO-TECHNE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.DANAHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.DANAHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 38.DANAHER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 39.FUJIFILM: NET SALES, 2018–2020 ($MILLION)
FIGURE 40.FUJIFILM: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 41.LONZA: NET SALES, 2017–2019 ($MILLION)
FIGURE 42.LONZA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 43.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 45.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 46.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 47.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 48.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 49.SARTORIUS: NET SALES, 2017–2019 ($MILLION)
FIGURE 50.SARTORIUS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 51.SARTORIUS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 52.THERMO FISHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 53.THERMO FISHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 54.THERMO FISHER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 55.TAKARA GROUP: NET SALES, 2017–2019 ($MILLION)
FIGURE 56.TAKARA GROUP: REVENUE SHARE, BY SEGMENT, 2019 (%)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の遺伝子治療細胞培養培地市場2020年-2027年:培地種類別(血清含有培地、無血清培地、幹細胞培地、特殊培地、合成培地、溶原培地、カスタム培地、その他)、ウイルスベクター別、エンドユーザー別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆